Evaluating the utility of the HTRF® Transcreener™ ADP assay technology: A comparison with the standard HTRF assay technology

Analytical Biochemistry

Volumn 391, Issue 1, 2009, Pages 31-38

  Hong, Lin ^a   Quinn, Christopher M ^a   Jia, Yong ^a  

^a GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION   (United States)

Author keywords

ADP; ATPase; HTRF; Inhibitor; Kinase assay; Transcreener

Indexed keywords

ADMINISTRATIVE DATA PROCESSING; CHEMICAL DETECTION; DRUG PRODUCTS; MONOCLONAL ANTIBODIES;

ATPASE; HTRF; INHIBITOR; KINASE ASSAYS; TRANSCREENER;

ENZYMES;

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATASE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; MONOCLONAL ANTIBODY;

ARTICLE; CONTROLLED STUDY; DRUG RESEARCH; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME ASSAY; ENZYME KINETICS; ENZYME SUBSTRATE; HIGH THROUGHPUT SCREENING; IC 50; INHIBITION KINETICS; INTERMETHOD COMPARISON; MOLECULAR INTERACTION; PRIORITY JOURNAL; STEADY STATE;

EID: 67349233597     PISSN: 00032697     EISSN: 10960309     Source Type: Journal    
DOI: 10.1016/j.ab.2009.04.033     Document Type: Article

References (49)

1. Degorce F. HTRF: pioneering technology for high-throughput screening. Exp. Opin. Drug Discov. 1 (2006) 753-764
2. Bazin H., Trinquet E., and Mathis G. Time resolved amplification of cryptate emission: a versatile technology to trace biomolecular interactions. Rev. Mol. Biotechnol. 82 (2002) 233-250
3. Bazin H., Préaudat M., Trinquet E., and Mathis G. Homogeneous time resolved fluorescence resonance energy transfer using rare earth cryptate as a tool for probing molecular interactions in biology. Spectrochim. Acta A 57 (2001) 2197-2211
4. Mathis G. Probing molecular interactions with homogeneous techniques bases on rare earth cryptate and fluorescence energy transfer. Clin. Chem. 41 (1995) 1391-1397
5. Mathis G. Rare earth cryptate and homogeneous fluoroimmunoassays with human sera. Clin. Chem. 39 (1993) 1953-1959
6. Mathis G. HTRF technology. J. Biomol. Screen. 4 (1999) 309-313
7. Manning G., Whyte D.B., Martinez R., Hunter T., and Sudarsanam S. The protein kinase complement of the human genome. Science 298 (2002) 1912-1934
8. Hunter T. Signaling: 2000 and beyond. Cell 100 (2000) 113-127
9. Mazitschek R., and Giannis A. Inhibitors of angiogenesis and cancer related receptor tyrosine kinases. Curr. Opin. Chem. Biol. 8 (2004) 432-441
10. Myers M.R., He W., and Hulme C. Inhibitors of tyrosine kinases involved in inflammation and autoimmune disease. Curr. Pharm. Des. 3 (1997) 473-502
11. Vlahos C.J., McDowell S.A., and Clerk A. Kinases as therapeutic targets for heart failure. Nat. Rev. Drug Discov. 2 (2003) 99-113
12. Resnick L., and Fennell M. Targeting JNK3 for the treatment of neurodegenerative disorders. Drug Discov. Today 9 (2004) 932-939
13. Cohen P. The development and therapeutic potential of protein kinase inhibitors. Curr. Opin. Chem. Biol. 3 (1999) 459-465
14. Cohen P. Protein kinases: the major drug targets of the twenty-first century?. Nat. Rev. Drug Discov. 1 (2002) 309-315
15. Levitzki A. Protein kinase inhibitors as a therapeutic modality. Acc. Chem. Res. 36 (2003) 462-469
16. Jia Y., Quinn C.M., Kwak S., and Talanian R.V. Current in vitro kinase assay technologies: the quest for a universal format. Curr. Drug Discov. Technol. 5 (2008) 59-69
17. von Ahsen O., and Bömer U. High-throughput screening for kinase inhibitors. ChemBioChem 6 (2005) 481-490
18. Sittampalam G.S., Kahl S.D., and Janzen W.P. High-throughput screening: advances in assay technologies. Curr. Opin. Chem. Biol. 1 (1997) 384-391
19. Minor L. Assays for membrane tyrosine kinase receptors: methods for high-throughput screening and utility for diagnostics. Exp. Rev. Mol. Diagn. 5 (2005) 561-571
20. Jia Y., Gu X.-J., Brinker A., and Warmuth M. Measuring the tyrosine kinase activity: a review of biochemical and cellular assay technologies. Exp. Opin. Drug Discov. 3 (2008) 959-978
21. Zaman G.J.R., Garritsen A., de Boer T., and van Boeckel C.A.A. Fluorescence assays for high-throughput screening of protein kinases. Comb. Chem. High Throughput Screen. 6 (2003) 313-320
22. Lowery R.G., and Kleman-Leyer K. Transcreener: screening enzymes involved in covalent regulation. Exp. Opin. Ther. Targets 10 (2006) 179-190
23. Huss K.L., Blonigen P.E., and Campbell R.M. Development of a Transcreener kinase assay for protein kinase A and demonstration of concordance of data with a filter-binding assay format. J. Biomol. Screen. 12 (2007) 578-584
24. Klink T.A., Kleman-Leyer K.M., Kopp A., Westermeyer T.A., and Lowery R.G. Evaluating PI3 kinase isoforms using Transcreener ADP assays. J. Biol. Screen. 13 (2008) 476-485
25. Jia Y. Current status of HTRF technology in kinase assays. Exp. Opin. Drug Discov. 3 (2008) 1461-1474
26. Beasley J.R., McCoy P.M., Walker T.L., and Dunn D.A. Miniaturized, ultra-high-throughput screening of tyrosine kinases using homogeneous, competitive fluorescence immunoassays. Assay Drug Dev. Technol. 2 (2004) 141-151
27. Moshinsky D.J., Ruslim L., Blake R.A., and Tang F. A widely applicable, high-throughput TR-FRET assay for the measurement of kinase autophosphorylation: VEGFR-2 as a prototype. J. Biomol. Screen. 8 (2003) 447-452
28. Klumpp M., Boettcher A., Becker D., Meder G., Blank J., Leder L., Forstner M., Ottl J., and Mayr L.M. Readout technologies for highly miniaturized kinase assays applicable to high-throughput screening in a 1536-well format. J. Biomol. Screen. 11 (2006) 617-633
29. Park Y.-W., Cummings R.T., Wu L., Zheng S., Cameron P.M., Woods A., Zaller D.M., Marcy A.I., and Hermes J.D. Homogeneous proximity tyrosine kinase assays: scintillation proximity assay versus homogeneous time-resolved fluorescence. Anal. Biochem. 269 (1999) 94-104
30. von Ahsen O., Schmidt A., Klotz M., and Parczyk K. Assay concordance between SPA and TR-FRET in high-throughput screening. J. Biomol. Screen. 11 (2006) 606-616
31. Ohml N., Wingfield J.M., Yazawa H., and Inagaki O. Development of a homogeneous time-resolved fluorescence assay for high-throughput screening to identify Lck inhibitors: comparison with scintillation proximity assay and streptavidin-coated plate assay. J. Biomol. Screen. 5 (2000) 463-470
32. Newman M., and Josiah S. Utilization of fluorescence polarization and time resolved fluorescence resonance energy transfer assay formats for SAR studies: Src kinase as a model system. J. Biomol. Screen. 9 (2004) 525-532
33. Jia Y., Quinn C.M., Clabbers A., Talanian R., Xu Y., Wishart N., and Allen H. Comparative analysis of various in vitro COT kinase assay formats and their applications in inhibitor identification and characterization. Anal. Biochem. 350 (2006) 268-276
34. Jia Y., Quinn C.M., Gagnon A.I., and Talanian R. Homogeneous time-resolved fluorescence and its applications for kinase assays in drug discovery. Anal. Biochem. 356 (2006) 273-281
35. Harbert C., Marshall J., Soh S., and Steger K. Development of a HTRF kinase assay for determination of Syk activity. Curr. Chem. Genomics 1 (2008) 20-26
36. Sugita H., Dan S., Kong D., Tomida A., and Yamori T. A new evaluation method for quantifying PI3K activity by HTRF assay. Biochem. Biophys. Res. Commun. 377 (2008) 941-945
37. 33P-ATP plate assay formats. J. Exp. Ther. Oncol. 4 (2004) 111-119
38. Dufau I., Lazzari A., Samson A., Pouny I., and Ausseil F. Optimization of homogeneous assay for kinase inhibitors in plant extracts. Assay Drug Dev. Technol. 6 (2008) 673-682
39. Paez J.C., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., Herman P., Kaye F.J., Lindeman N., Boggon T.J., Naoki K., Sasaki H., Fujii Y., Eck M.J., Sellers W.R., Johnson B.E., and Meyerson M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 (2004) 1497-1500
40. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., Harris P.L., Haserlat S.M., Supko J.G., Haluska F.C., Louis D.N., Christiani D.C., Settleman J., and Haber D.A. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell-lung cancer to gefitinib. N. Engl. J. Med. 350 (2004) 2129-2139
41. Pao W., Miller V., Zakowski M., Doherty J., Politi K., Sarkaria I., Singh B., Heelan R., Rusch V., Fulton L., Mardis E., Kupfer D., Wilson R., Kris M., and Varmus H. EGF receptor gene mutations are common in lung cancers from "never smokers" and correlate with sensitivity of tumors to gefitinib (Iressa) and erlotinib (Tarceva). Proc. Natl. Acad. Sci. USA 101 (2004) 13306-13311
42. Kobayshi S., Boggon T.J., Dayaram T., Janne P.A., Kocher O., Meyerson M., Johnson B.E., Eck M.J., Tenen D.G., and Halmos B. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 352 (2005) 786-792
43. Pao W., Miller V.A., Politi K.A., Reily G.J., Somwar R., Zakowski M.E., Kris M.G., and Varmus H. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2 (2005) 225-235
44. Yun C.-H., Boggon T.J., Li Y., Woo M.S., Greulich H., Meyerson M., and Eck M. Structure of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 11 (2007) 217-227
45. Zhang J.-H., Chung T.D.Y., and Oldenburg K.R. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen. 4 (1999) 67-73
46. Chen G., Porter M.D., Bristol J.R., Fitzgibbon M.J., and Pazhanisamy S. Kinetic mechanism of the p38-α MAP kinases: phosphoryl transfer to synthetic peptides. Biochemistry 39 (2000) 2079-2087
47. Ward N.E., and O'Brian C.A. The intrinsic ATPase activity of protein kinase C is catalyzed at the active site of the enzyme. Biochemistry 31 (1992) 5905-5911
48. Armstrong R.N., Kondo H., and Kaiser E.T. Cyclic AMP-dependent ATPase activity of bovine heart protein kinase. Proc. Natl. Acad. Sci. USA 76 (1979) 722-725
49. Kashem M.A., Nelson R.M., Yingling J.D., Pullen S.S., Prokopowicz III A.S., Jones J.W., Wolak J.P., Rogers G.R., Morelock M.M., Snow R.J., Homon C.A., and Jakes S. Three mechanistically distinct kinase assays compared: measurement of intrinsic ATPase activity identified the most comprehensive set of ITK inhibitors. J. Biomol. Screen. 12 (2007) 70-83